GT Biopharma, Inc.
GTBP· Nasdaq
GTBPGT Biopharma, Inc.
Filed Nov 14, 2025 · 10-Q · 45 days after period end · 0001493152-25-023400
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Net Income | $8.30M | -$3.41M | -$2.42M | -$6.88M |
| EPS Diluted | $1.04 | -$1.53 | -$1.77 | -$0.22 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR
ended Sep 30, 2025 · filed Nov 14, 2025 · 45 d after period end
